http://rdf.disgenet.org/resource/nanopub/NP675044.RAV1r-17uRhOmJODS274KTW2qtK15vquCwwlWuioYxYlg
type: Nanopublication
created: 2016-05-13T12:46:51+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

http://rdf.disgenet.org/resource/nanopub/NP675044.RAV1r-17uRhOmJODS274KTW2qtK15vquCwwlWuioYxYlg130_assertion
type: Assertion
description: [Although extensively studied in plasma cell neoplasms, there is little information in the literature regarding FGFR3 expression in malignant lymphomas, and it is unclear whether lymphoma patients may also benefit from anti-FGFR3 therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/18528286
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0